These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18050723)

  • 41. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 45. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 47. Prostate cancer - 6th International Congress.
    Figg WD; Ockers S
    IDrugs; 2006 Oct; 9(10):675-8. PubMed ID: 17016769
    [No Abstract]   [Full Text] [Related]  

  • 48. Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option?
    Brewster SF
    BJU Int; 2008 Sep; 102(8):923-6. PubMed ID: 18647299
    [No Abstract]   [Full Text] [Related]  

  • 49. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical study of stage a prostatic cancer detected incidentally by transurethral resection of the prostate].
    Nakanishi S; Gotou T; Sawada A; Shibasaki N; Ishitoya T; Okumura K
    Hinyokika Kiyo; 2009 Jan; 55(1):5-8. PubMed ID: 19227204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Roobol MJ; Schröder FH
    J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
    [No Abstract]   [Full Text] [Related]  

  • 53. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
    Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
    J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Re: The influence of statin medications on prostate-specific antigen levels.
    Cicero AF; Derosa G; Gaddi AV
    J Natl Cancer Inst; 2009 Apr; 101(8):610; author reply 610-1. PubMed ID: 19351921
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in prostate cancer treatment.
    Saca-Hazboun H
    ONS Connect; 2008 Sep; 23(9):8-12. PubMed ID: 18807706
    [No Abstract]   [Full Text] [Related]  

  • 57. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
    Carlucci JR; Nabizada-Pace F; Samadi DB
    Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What to do with an abnormal PSA test.
    Loeb S; Catalona WJ
    Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M; Jonas D; Oremek GM
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In reply to Dr. Lee: are prostate cancers created equal?
    Lawrence G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1276; author reply 1276-7. PubMed ID: 19857792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.